nicotine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.38) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 13 (40.63) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, H; Jung, YJ; Oh, E | 1 |
| Campusano, JM; Carvajal-Oliveros, A; Dominguez-Baleón, C; Hernández-Vargas, R; Narváez-Padilla, V; Reynaud, E; Sánchez-Díaz, I; Zambrano-Tipan, D | 1 |
| Fu-Rong, H; Hai, W | 1 |
| Asadi-Shekaari, M; Eftekhar-Vaghefi, SH; Elyasi, L; Esmaeili-Mahani, S | 1 |
| Kohtala, S; Koski, SK; Leino, S; Rannanpää, S; Rantamäki, T; Salminen, O | 1 |
| Campos, C; Grady, SR; Quik, M | 1 |
| Agarwal, S; Bhatnagar, P; Chaturvedi, RK; Chauhan, LKS; Gupta, KC; Kumar, P; Patel, DK; Singh, MP; Singhal, NK; Tiwari, MN; Tiwari, SK | 1 |
| Gan, J; Liu, ZG; Pan, JL; Xie, CL; Zhang, SF | 1 |
| Fan, W; Hu, J; Huang, Z; Hui, Y; Ji, J; Liu, Y; Taylor, DH; Wu, J; Zeng, X; Zhu, C | 1 |
| Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M | 1 |
| Abin-Carriquiry, JA; Cassels, BK; Costa, G; Dajas, F; Rebolledo-Fuentes, M; Urbanavicius, J; Wonnacott, S | 1 |
| Akaike, A; Inden, M; Inoue, H; Izumi, Y; Kihara, T; Kitamura, Y; Sawada, H; Shimohama, S; Takahashi, R; Takata, K; Takeuchi, H; Taniguchi, T; Uemura, K; Yamakawa, K; Yamamoto, N; Yanagida, T | 1 |
| Kishimoto, K; Kitamura, Y; Minamino, H; Shibaike, T; Shimohama, S; Takata, K; Takeuchi, H; Taniguchi, T; Tsushima, J; Yanagida, T; Yasui, H | 1 |
| Campos, C; Langston, JW; McIntosh, JM; Parameswaran, N; Quik, M; Yeluashvili, M | 1 |
| Kawamata, J; Shimohama, S; Suzuki, S | 1 |
| Grady, SR; Hrachova, M; Huang, LZ; Mallela, A; McIntosh, JM; Park, KM; Quik, M | 1 |
| Ciobica, A; Hritcu, L; Padurariu, M | 1 |
| Bordia, T; McIntosh, JM; Quik, M | 1 |
| Dumery, B; Hapdey, C; Hirsch, EC; Marchand, V; Parain, K; Rousselet, E | 1 |
| ARZT, FC; BRAGAN, RA; DECATO, L; MALONE, MH | 1 |
| BOVET, D; DUREL, P; LONGO, V | 1 |
| BOVET, D; LONGO, VG | 1 |
| Ahtee, L; Janhunen, S; Tuominen, RK | 1 |
| Emre, M; Hanagasi, HA; Johnson, JO; Lees, A; Singleton, A | 1 |
| Choonara, YE; Pillay, V; Singh, N | 1 |
| Abin-Carriquiry, JA; Costa, G; Dajas, F; Ferreira, M; Urbanavicius, J; Wonnacott, S | 1 |
| Copeland, RL; Das, JR; Kanaan, YM; Taylor, RE; Tizabi, Y | 1 |
| Cox, H; Di Monte, D; Langston, JW; O'Leary, K; Parameswaran, N; Quik, M | 1 |
| Dumery, B; Hirsch, E; Marchand, V; Parain, K | 1 |
| Abín-Carriquiry, JA; Costa, G; Dajas, F; McGregor, R; Urbanavicius, J | 1 |
| Kaseda, Y; Kawakami, H; Kohriyama, T; Mitsuoka, T; Nakamura, S; Yamamura, Y; Yamashita, H | 1 |
| Hermida-Ameijeiras, A; Labandeira-García, JL; López-Real, AM; Méndez-Alvarez, E; Soto-Otero, R | 1 |
4 review(s) available for nicotine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Ganglionic Stimulants; Levodopa; Nicotine; Parkinsonian Disorders | 2014 |
α7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Disease Progression; Dopamine; Humans; Neurons; Neuroprotective Agents; Nicotine; Parkinson Disease; Parkinsonian Disorders; Receptors, Nicotinic; Signal Transduction; Smoking | 2012 |
Advances in the treatment of Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Antiparkinson Agents; Brain Tissue Transplantation; Cholinergic Antagonists; Deep Brain Stimulation; Dopamine Agonists; Enzyme Inhibitors; Fetal Tissue Transplantation; Genetic Therapy; Globus Pallidus; Humans; Iron Chelating Agents; Nanotechnology; Neuroprotective Agents; Nicotine; Parkinson Disease; Parkinsonian Disorders; Stem Cell Transplantation; Vaccination; Vitamins | 2007 |
Involvement of nicotinic acetylcholine receptors in the protection of dopamine terminals in experimental parkinsonism.
Topics: Animals; Cytoprotection; Dopamine; In Vitro Techniques; Nerve Endings; Neuroprotective Agents; Neurotoxins; Nicotine; Oxidopamine; Parkinsonian Disorders; Receptors, Nicotinic | 2001 |
28 other study(ies) available for nicotine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Effects of particulate matter and nicotine for the MPP+-induced SH-SY5Y cells: Implication for Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Neurons; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Particulate Matter | 2021 |
Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment.
Topics: Animals; Dopamine; Dopaminergic Neurons; Drosophila melanogaster; Humans; Nerve Tissue Proteins; Nicotine; Parkinsonian Disorders; Phenotype | 2023 |
[Modulation by desensitized nicotinic receptors on metabolism of DA in striatum derived from the hemiparkinsonian model].
Topics: Animals; Corpus Striatum; Dopamine; Monoamine Oxidase; Nicotine; Oxidopamine; Parkinsonian Disorders; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Nicotinic | 2016 |
Induction of cross-tolerance between protective effect of morphine and nicotine in 6-hydroxydopamine-induce neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Dopaminergic Neurons; Drug Tolerance; Humans; Morphine; Neuroprotective Agents; Nicotine; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Reactive Oxygen Species | 2019 |
Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Brain-Derived Neurotrophic Factor; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Furans; Levodopa; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Quinuclidines; Random Allocation | 2018 |
Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Central Nervous System; Cotinine; Dopamine; Dyskinesias; Mice; Mice, Knockout; Nicotine; Parkinsonian Disorders; Receptors, Nicotinic; Saccharin | 2013 |
Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism.
Topics: Animals; Blotting, Western; Brain; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Flow Cytometry; Immunohistochemistry; Lactic Acid; Mice; Nanoconjugates; Neurons; Neuroprotective Agents; Nicotine; Oxidative Stress; Parkinsonian Disorders; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Real-Time Polymerase Chain Reaction | 2013 |
Activation of α7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson's disease.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Apoptosis; Astrocytes; Cells, Cultured; Dopaminergic Neurons; Male; Membrane Potential, Mitochondrial; Mice, Inbred C57BL; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Oxidative Stress; Parkinsonian Disorders; Pars Compacta | 2015 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic | 2015 |
In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: implications for Parkinson's Disease.
Topics: Alkaloids; Animals; Antiparkinson Agents; Azocines; Bridged-Ring Compounds; Disease Models, Animal; Dopamine; Male; Microdialysis; Neostriatum; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Quinolizines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Receptors, Presynaptic; Substantia Nigra | 2008 |
Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
Topics: Animals; Behavior, Animal; Blotting, Western; Cholinergic Agents; Dopamine; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neurons; Nicotine; Parkinsonian Disorders; Receptors, Nicotinic; Rotenone; Substantia Nigra; Uncoupling Agents | 2009 |
Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Electron Spin Resonance Spectroscopy; Functional Laterality; Galantamine; Gene Expression Regulation; Male; Mecamylamine; Methamphetamine; Motor Activity; Neuroprotective Agents; Nicotine; Nicotinic Antagonists; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Nicotinic; RNA, Messenger; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2008 |
Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage.
Topics: Animals; Biomarkers; Cell Count; Disease Models, Animal; Dopamine; Female; Melanins; Microglia; Neurons; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Receptors, Nicotinic; Saimiri; Substantia Nigra; Treatment Outcome; Tyrosine 3-Monooxygenase; Up-Regulation | 2010 |
Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Autoradiography; Benserazide; Cotinine; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Receptors, Nicotinic | 2012 |
The effects of short-term nicotine administration on behavioral and oxidative stress deficiencies induced in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Disease Models, Animal; Ganglionic Stimulants; Glutathione Peroxidase; Lipid Peroxidation; Male; Maze Learning; Memory, Short-Term; Nicotine; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Temporal Lobe | 2012 |
The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Topics: Animals; Antiparkinson Agents; Autoradiography; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic | 2013 |
Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Nicotine; Parkinsonian Disorders; Smoking | 2003 |
RESERPINE-NICOTINE INDUCED PARKINSONISM IN MICE.
Topics: Anticonvulsants; Atropine; Lactose; Mice; Muscle Relaxants, Central; Neostigmine; Nicotine; Parkinsonian Disorders; Pharmacology; Phenobarbital; Research; Reserpine; Scopolamine; Tetraethylammonium Compounds; Toxicology; Trihexyphenidyl | 1965 |
[Antagonism of dibenzothiazine derivatives (diparcol, parsidol, phenergan) towards the central effects of nicotine; correspondence with clinical experimentation in Parkinson's disease].
Topics: Empirical Research; Histamine Antagonists; Nicotine; Parkinson Disease; Parkinsonian Disorders; Phenothiazines; Promethazine | 1950 |
The action on nicotine-induced tremors of substances effective in Parkinsonism.
Topics: Humans; Nicotine; Parkinsonian Disorders; Tremor | 1951 |
Comparison of the effects of nicotine and epibatidine given in combination with nomifensine on rotational behaviour in rats.
Topics: Adrenergic Agents; Animals; Brain; Bridged Bicyclo Compounds, Heterocyclic; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Male; Motor Activity; Nicotine; Nicotinic Agonists; Nomifensine; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Wistar | 2005 |
Smoking-responsive juvenile-onset Parkinsonism.
Topics: Adult; Humans; Male; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Smoking; Tomography, Emission-Computed, Single-Photon; Tropanes | 2007 |
Nicotine induces tyrosine hydroxylase plasticity in the neurodegenerating striatum.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Axons; Corpus Striatum; Denervation; Dopamine; Down-Regulation; Levodopa; Male; Nerve Degeneration; Neuronal Plasticity; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2007 |
Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity.
Topics: Annexin A5; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Humans; Isoquinolines; Neuroblastoma; Neurotoxins; Nicotine; Parkinsonian Disorders | 2007 |
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Rhythm; Dyskinesia, Drug-Induced; Levodopa; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra; Time Factors | 2007 |
Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice.
Topics: Animals; Axons; Cotinine; Dopamine; Male; Mice; Mice, Inbred C57BL; Neostriatum; Nerve Degeneration; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism.
Topics: Adult; Chewing Gum; Evoked Potentials; Female; Humans; Male; Middle Aged; Nicotine; Parkinsonian Disorders; Reaction Time; Smoking | 2002 |
Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Corpus Striatum; Cotinine; Disease Models, Animal; Drug Interactions; Female; Male; Neurotoxicity Syndromes; Nicotine; Nicotinic Agonists; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2002 |